Korsana Biosciences, Inc. KRSA
Set alert
31.66 USD +1.52 +5.04%
At close · Nov 2
31.66 0.00 0.00%
After hours · Nov 2, 7:30 PM ET
29.93 Day range 31.91
7.19 52-week range 59.36
- YTD
- +256.13%
- 1 year
- +141.86%
- Open
- 30.00
- Prev close
- 30.14
- Mkt cap
- 1.44B
- Vol
- 197.54K
- Avg vol
- 72.38K
- EPS
- -7.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 29.93
- High
- 31.91
- Forward P/E
- -8.90
- Beta
- 1.84
- Short ratio
- 0.26
- Inst. own
- 45.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 31.09
- 200-d avg
- 21.95
- 1y target
- 44.00
3M chart
Events in this range
- Aug 4, 2026Earnings: -0.41; estimate -3.45; surprise 88.12%
- Sep 11, 2026Rating: UBS · — → Buy
- Sep 14, 2026Rating: TD Cowen · — → Buy
- Sep 14, 2026Rating: Stifel · — → Buy
- Sep 28, 2026Rating: Guggenheim · — → Buy
- Oct 5, 2026Rating: Wedbush · — → Outperform
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Sep 3, 2026 | 2 months ago |
| MACD: Buy Signal | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 1.44B
- Enterprise value
- 223.31M
- Trailing P/E
- 0.00
- Forward P/E
- -8.90
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -7.07
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 134.16M
- Total debt
- 1.10M
- Return on equity
- 0.00%
- Shares outstanding
- 45.54M
- Short % of float
- 0.00%
- 50-day average
- 31.09
- 200-day average
- 21.95
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 44.00 +39.0% upside
Now 31.66
- Target (low)
- 8.00
- Target (mean)
- 44.00
- Target (high)
- 70.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 0.00.
Financials — quick view
KRSA Revenue — quarterly 0
KRSA Net income — quarterly -1.75M
KRSA EPS — quarterly -2.87
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.84695 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -3.45 | -0.41 | +3.04 | +88.12% |
| May 5, 2026 | Mar 31, 2026 | -2.66 | -2.66 | 0.00 | 0.00% |
| Mar 17, 2026 | Dec 31, 2025 | -2.66 | -1.75 | +0.91 | +34.21% |
| Nov 12, 2025 | Sep 30, 2025 | -121.80 | -0.30 | +121.50 | +99.75% |
| Aug 5, 2025 | Jun 30, 2025 | — | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Wedbush | init | — | Outperform |
| Sep 28, 2026 | Guggenheim | init | — | Buy |
| Sep 14, 2026 | Stifel | init | — | Buy |
| Sep 14, 2026 | TD Cowen | init | — | Buy |
| Sep 11, 2026 | UBS | init | — | Buy |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korsana.com
News
- Korsana Biosciences to Participate in Upcoming Investor Conferences
- Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44
- Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70
- Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43
- UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
- Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
- Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
- CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
- Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
Your note
Sign in to keep a note on KRSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kalehua Capital Management LLC | 0.52% | 235,907 | 7.47M | Jun 29, 2026 |
| FMR, LLC | 0.20% | 92,793 | 2.94M | Jun 29, 2026 |
| Balyasny Asset Management LP | 0.10% | 45,359 | 1.44M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 0.09% | 42,680 | 1.35M | Jun 29, 2026 |
| Braidwell LP | 0.05% | 22,413 | 709.60K | Jun 29, 2026 |
| Citadel Advisors Llc | 0.02% | 8,542 | 270.44K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.07% | 31,141 | 985.92K | Aug 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.03% | 15,200 | 481.23K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.02% | 8,668 | 274.43K | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.02% | 8,186 | 259.17K | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.01% | 4,416 | 139.81K | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.01% | 5,351 | 169.41K | Aug 30, 2026 |